Recombinant Influenza Vaccination in U.S. Nursing Homes

PHASE4UnknownINTERVENTIONAL
Enrollment

1,989

Participants

Timeline

Start Date

July 20, 2019

Primary Completion Date

August 31, 2023

Study Completion Date

December 31, 2023

Conditions
InfluenzaInfluenza -Like IllnessInfluenza, Human
Interventions
BIOLOGICAL

Recombinant Influenza Vaccine

Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.

BIOLOGICAL

Standard Dose Quadrivalent Influenza Vaccine

Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine

Trial Locations (1)

23510

Insight Therapeutics, LLC, Norfolk

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

collaborator

Brown University

OTHER

collaborator

Case Western Reserve University

OTHER

lead

Insight Therapeutics, LLC

OTHER